NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients With Retinitis Pigmentosa NACAttack, A Phase III, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study E ...
National Eye Institute (NEI);Duke University;Emory University;Massachusetts Eye and Ear Infirmary;Mayo Clinic;Medical College of Wisconsin;Retina Foundation of the Southwest;Stanford University;University of California, Davis;University of Florida;University of Illinois at Chicago;University of Iowa;University of Miami;University of Michigan;University of Minnesota;University of Oklahoma;University of Southern California;University of Utah;University of Washington;University of Wisconsin, Madison;Vanderbilt University;Vitreo Retinal Associates, PA;University of Houston;Medical University of Graz;McGill University;Universität Tübingen;Centro Medico ABC;Radboud University Medical Center;University of Amsterdam;University Hospital, Basel, Switzerland;University College London Hospitals;Northwestern University National Eye Institute (NEI);Duke University;Emory University;Massachusetts Eye and Ear Infirmary;Ma ...
Not yet recruiting
18 Years
65 Years
All
438
Phase 3
United States;Austria;Canada;Germany;Mexico;Netherlands;Switzerland;United Kingdom
Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome
Safety and Efficacy of NPI-001 Tablets Versus Placebo for Treatment of Retinitis Pigmentosa Associated With Usher Syndrome Safety and Efficacy of NPI-001 Tablets Versus Placebo for Treatment of Retinitis Pigmentosa Associat ...
A Phase 1 Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of N-Acetylcysteine (NAC) in Patients With Retinitis Pigmentosa A Phase 1 Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of N-Acetylcyst ...
A Phase 1 Open Label Dose Ranging Study to Assess the Safety and Tolerability of N-Acetylcysteine (NAC) in Patients With Retinitis Pigmentosa (FIGHT-RP1 Study) A Phase 1 Open Label Dose Ranging Study to Assess the Safety and Tolerability of N-Acetylcysteine (N ...